GlassScriptPhysician profile
Ali Alnashif
NPI 1699731430
$3,051.93
in general payments reported to CMS, 2019-2025
26 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $387 · 2022: $70.29 · 2023: $216 · 2024: $126 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.00 |
| Education | $116.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $370.76 | 2019-2025 | Nucala |
| Mallinckrodt Hospital Products INC. | $241.70 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $227.30 | 2019-2025 | Airsupra |
| Grifols USA, LLC | $225.79 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $220.00 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Mylan Specialty L.P. | $183.14 | 2019-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $180.48 | 2019 | |
| Mallinckrodt Enterprises LLC | $157.45 | 2019 | |
| Insmed, INC. | $105.64 | 2022-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $97.12 | 2019-2020 | |
| Genzyme Corporation | $89.89 | 2019-2025 | |
| Circassia INC. | $88.98 | 2019 | |
| Amgen INC. | $81.39 | 2019-2020 | |
| Viatris Specialty LLC | $71.23 | 2025 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $61.24 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $51.52 | 2024-2025 | Dupixent |
| Philips North America LLC | $47.13 | 2019 | |
| Shire North American Group INC | $35.41 | 2019 | |
| Genentech USA, INC. | $22.88 | 2019 | |
| Lilly USA, LLC | $20.23 | 2025 | Zepbound |
| Ani Pharmaceuticals, INC. | $20.02 | 2022 | |
| Advanced Respiratory, INC | $19.12 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.00 | 2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $15.49 | 2019 | |
| Janssen Pharmaceuticals, INC | $2.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Alnashif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.